文献速递消化道肿瘤放疗

奥地利食管鳞癌放疗实践调查

Practice of radiation therapy for squamous cell esophageal cancer in Austria - a survey on behalf of the ÖGRO-GIT.
PubMed 文献 · Radiat Oncol · 2026-04-03

该调查向奥地利全部14家公立放射肿瘤科发放匿名问卷,评估食管鳞癌放化疗的实践模式。应答率93%,各中心在EUS和PET-CT使用、根治性总剂量、选择性淋巴结照射范围及OAR剂量限值方面存在差异,与主要国际指南不一致。

要点

  • 各中心均采用IMRT联合IGRT,化疗首选每周卡铂/紫杉醇。
  • 新辅助中位剂量41.4 Gy,根治性中位剂量57.7 Gy。
  • EUS使用61%、PET-CT使用54%、功能肺检测仅46%。

核心结论

  • 奥地利各中心在先进分期检查使用、根治性总剂量、选择性淋巴结照射及OAR剂量限值方面与主要指南存在不一致。

研究设计与样本

  • 向奥地利全部14家公立放射肿瘤科发放57项匿名问卷,结果作描述性分析并与两部主要国际指南最新版比较。

主要发现

  • 应答率93%,每中心每年中位患者数13例(5-30例)。
  • EUS使用率61%,PET-CT使用率54%,功能肺检测报告率仅46%。
  • 无中心报告预防性置入喂养管或支架。
  • 新辅助化疗首选每周卡铂/紫杉醇占85%,根治性占69%。
  • 新辅助中位剂量41.4 Gy(41.4-50.4 Gy),根治性中位剂量57.7 Gy(50.4-66 Gy)。

关键数值与推荐

  • 所有中心采用常规分割IMRT联合(多为每日)IGRT。
  • 局部晚期合适患者一般首选新辅助治疗,但颈部肿瘤位置除外。
  • 靶区范围差异较大,约半数中心偏好受累淋巴结照射而非选择性淋巴结照射。
  • 主要OAR定义一致,但OAR剂量限值差异广泛。
  • 77%的中心对患者进行至少5年的密集随访。

临床怎么用

  • 应规范EUS和PET-CT等分期检查的使用以提高分期一致性。
  • 需统一根治性放疗总剂量及受累与选择性淋巴结照射的靶区范围。
  • 应统一OAR剂量限值以减少中心间差异。

局限性

  • 仅调查奥地利公立放射肿瘤科,结果外推需谨慎。
  • 为问卷描述性分析,未报告病例级疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the patterns of care for chemoradiation for squamous cell carcinoma (SCC) of the esophagus in Austria. METHODS: An anonymous questionnaire (57 items) was sent to all 14 public Austrian radiation oncology departments. Results were analyzed descriptively and compared to the latest versions of two major international guidelines. RESULTS: The response rate was 93%. The median number of patients per center per year was 13 (5-30). All centers reported pretreatment multidisciplinary evaluation. Work-up generally included endoscopy and cross-sectional imaging of chest/abdomen (mainly CT). EUS was used by 61% and PET-CT by 54%. Functional lung testing was reported only by 46%. No center reported the prophylactic placement of feeding tubes or stents. All centers employed IMRT in conventional fractionation with (mostly daily) IGRT. Weekly Carboplatin/Paclitaxel was the preferred chemotherapy regimen in both neoadjuvant (85%) and definitive (69%) settings, although only SCC were included. Neoadjuvant treatment was generally preferred for locally advanced stages in suitable patients, except for those with cervical tumor locations. Median doses to the primary tumor were 41.4 Gy (41.4-50.4 Gy) in the neoadjuvant and 57.7 Gy (50.4-66 Gy) in the definitive setting. Target volumes varied considerably (roughly half of the centers preferred involved vs. elective nodal irradiation). Definition of main OARs was uniform, but dose constraints to OAR differed widely. Intensive follow-up was performed in 77% for at least 5 years. CONCLUSION: The use of advanced staging procedures, prescription of total (boost) doses in the definitive setting, the issue of involved vs. elective nodal irradiation, and dose constraints to OARs were identified as major areas of disagreement between Austrian centers and inconsistencies with major guidelines.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gerum S, Clemens P, Salinger J, et al. Practice of radiation therapy for squamous cell esophageal cancer in Austria - a survey on behalf of the ÖGRO-GIT. Radiat Oncol. 2026. PMID: 41933377. doi:10.1186/s13014-026-02808-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。